AtlantiCare
en Español
 
AboutHealth ServicesHealth ConditionsLocationsEvents & CoursesCommunityWays of Giving
  Search  
 
Health News
Today's Headlines
Health Alerts
Health News Feature
Future of Medicine
Health Observances
Product Recalls
Health Library
Illnesses & Conditions
Drug Guide
FDA Drug Approvals
Medical Tests
Self-Help Resources
Complementary Medicine
Medline Search
Health Topics
Allergies
Asthma
Back Pain
Cancer
Caregiver
Depression
Diabetes
GERD
Heart
Kidney
Men's Health
Orthopedic
Parenting
Patient Safety
Pregnancy
Senior
Stress
Stroke
Weight Mgmt
Women's Health
Healthy Living
Fitness
Nutrition
Mind & Body
Family & Home
Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Molecule Uses Cellular Recycling to Treat Kidney Cancer


Finding represents a major shift for targeted therapy, study says

MONDAY, July 7 (HealthDay News) -- A molecule that uses a cellular recycling process called autophagy to kill cancer cells has been identified by Stanford University researchers.

Autophagy is normally used by cells to conserve resources during times of stress.

"Increasing evidence implicates a role for autophagy in cancer, but it is not well understood how cellular and environmental cues drive authophagic cells down survival or death pathways," study senior author Dr. Amato J. Giaccia said in a prepared statement.

In this study, Giaccia and his colleagues focused on renal cell carcinoma (RCC), the most common form of kidney cancer. In most cases, RCC is caused by a mutation of the von Hippel-Lindau (VHL) tumor suppressor gene and often fails to respond to treatment.

"Since RCCs have a poor prognosis and are refractory to standard chemotherapy, there is a need to develop new therapies for kidney cancer," Giaccia said.

The researchers searched for molecules that could destroy VHL-deficient kidney cancer and identified a molecule called STF-62247, which enhanced autophagy in VHL-deficient cells. The molecule didn't affect cells with normal VHL.

"We have found a small molecule that selectively induces cell death in VHL-deficient cells, such as those that are found in kidney cancer. This represents a paradigm shift for targeted therapy," Giaccia said.

The study was to be published in the July 8 issue of the journal Cancer Cell.

More information

The American Cancer Society has more about kidney cancer.

SOURCE: Cell Press, news release, July 7, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay
 
 
Notice of Privacy Practices | | Disclaimer    © 2006 AtlantiCare AtlantiCare Access
 

  Powered by HEALTHvision